Analysis of Different Innovative Formulations of Curcumin for Improved Relative Oral Bioavailability in Human Subjects

Overview

Journal Eur J Nutr

Specialty Nutritional Sciences

Date 2017 Feb 17

PMID 28204880

Citations 67

Authors

Martin Purpura

Ryan P Lowery

Jacob M Wilson

Haider Mannan

Gerald Munch

Valentina Razmovski-Naumovski

Affiliations

Soon will be listed here.

Abstract

Purpose: The optimal health benefits of curcumin are limited by its low solubility in water and corresponding poor intestinal absorption. Cyclodextrins (CD) can form inclusion complexes on a molecular basis with lipophilic compounds, thereby improving aqueous solubility, dispersibility, and absorption. In this study, we investigated the bioavailability of a new γ-cyclodextrin curcumin formulation (CW8). This formulation was compared to a standardized unformulated curcumin extract (StdC) and two commercially available formulations with purported increased bioavailability: a curcumin phytosome formulation (CSL) and a formulation of curcumin with essential oils of turmeric extracted from the rhizome (CEO).

Methods: Twelve healthy human volunteers participated in a double-blinded, cross-over study. The plasma concentrations of the individual curcuminoids that are present in turmeric (namely curcumin, demethoxycurcumin, and bisdemethoxycurcumin) were determined at baseline and at various intervals after oral administration over a 12-h period.

Results: CW8 showed the highest plasma concentrations of curcumin, demethoxycurcumin, and total curcuminoids, whereas CSL administration resulted in the highest levels of bisdemethoxycurcumin. CW8 (39-fold) showed significantly increased relative bioavailability of total curcuminoids (AUC) in comparison with the unformulated StdC.

Conclusion: The data presented suggest that γ-cyclodextrin curcumin formulation (CW8) significantly improves the absorption of curcuminoids in healthy humans.

Citing Articles

Curcumin Solubility and Bioactivity Enhancement Through Amorphization with Tryptophan via Supercritical Fluid Technology.

Garbiec E, Rosiak N, Sip S, Zalewski P, Cielecka-Piontek J Int J Mol Sci. 2025; 26(2).

PMID: 39859569 PMC: 11766122. DOI: 10.3390/ijms26020855.

Unlocking the Potential of Senolytic Compounds: Advancements, Opportunities, and Challenges in Ageing-Related Research.

Gomez L, Jurk D Subcell Biochem. 2024; 107:91-116.

PMID: 39693021 DOI: 10.1007/978-3-031-66768-8_5.

Clinical Trial Findings and Drug Development Challenges for Curcumin in Infectious Disease Prevention and Treatment.

El Oirdi M, Farhan M Life (Basel). 2024; 14(9).

PMID: 39337921 PMC: 11432846. DOI: 10.3390/life14091138.

The Bright Side of Curcumin: A Narrative Review of Its Therapeutic Potential in Cancer Management.

Amaroli A, Panfoli I, Bozzo M, Ferrando S, Candiani S, Ravera S Cancers (Basel). 2024; 16(14).

PMID: 39061221 PMC: 11275093. DOI: 10.3390/cancers16142580.

Nanocarriers for natural polyphenol senotherapeutics.

Joma N, Bielawski P, Saini A, Kakkar A, Maysinger D Aging Cell. 2024; 23(5):e14178.

PMID: 38685568 PMC: 11113259. DOI: 10.1111/acel.14178.

References

Liu A, Lou H, Zhao L, Fan P . Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J Pharm Biomed Anal. 2005; 40(3):720-7. DOI: 10.1016/j.jpba.2005.09.032. View

Cuomo J, Appendino G, Dern A, Schneider E, McKinnon T, Brown M . Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod. 2011; 74(4):664-9. DOI: 10.1021/np1007262. View

Karunaweera N, Raju R, Gyengesi E, Munch G . Plant polyphenols as inhibitors of NF-κB induced cytokine production-a potential anti-inflammatory treatment for Alzheimer's disease?. Front Mol Neurosci. 2015; 8:24. PMC: 4468843. DOI: 10.3389/fnmol.2015.00024. View

Lev-Ari S, Maimon Y, Strier L, Kazanov D, Arber N . Down-regulation of prostaglandin E2 by curcumin is correlated with inhibition of cell growth and induction of apoptosis in human colon carcinoma cell lines. J Soc Integr Oncol. 2006; 4(1):21-6. View

Hassaninasab A, Hashimoto Y, Tomita-Yokotani K, Kobayashi M . Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism. Proc Natl Acad Sci U S A. 2011; 108(16):6615-20. PMC: 3080977. DOI: 10.1073/pnas.1016217108. View

Ireson C, Orr S, Jones D, Verschoyle R, Lim C, Luo J . Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res. 2001; 61(3):1058-64. View

Vareed S, Kakarala M, Ruffin M, Crowell J, Normolle D, Djuric Z . Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev. 2008; 17(6):1411-7. PMC: 4138955. DOI: 10.1158/1055-9965.EPI-07-2693. View

Antony B, Merina B, Iyer V, Judy N, Lennertz K, Joyal S . A Pilot Cross-Over Study to Evaluate Human Oral Bioavailability of BCM-95CG (Biocurcumax), A Novel Bioenhanced Preparation of Curcumin. Indian J Pharm Sci. 2010; 70(4):445-9. PMC: 2792534. DOI: 10.4103/0250-474X.44591. View

Lao C, Ruffin 4th M, Normolle D, Heath D, Murray S, Bailey J . Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006; 6:10. PMC: 1434783. DOI: 10.1186/1472-6882-6-10. View

10.

Jagetia G, Aggarwal B . "Spicing up" of the immune system by curcumin. J Clin Immunol. 2007; 27(1):19-35. DOI: 10.1007/s10875-006-9066-7. View

11.

Asher G, Spelman K . Clinical utility of curcumin extract. Altern Ther Health Med. 2013; 19(2):20-2. View

12.

Szejtli J . Medicinal applications of cyclodextrins. Med Res Rev. 1994; 14(3):353-86. DOI: 10.1002/med.2610140304. View

13.

Schiborr C, Kocher A, Behnam D, Jandasek J, Toelstede S, Frank J . The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res. 2014; 58(3):516-27. DOI: 10.1002/mnfr.201300724. View

14.

Hansen E, Krautwald M, Maczurek A, Stuchbury G, Fromm P, Steele M . A versatile high throughput screening system for the simultaneous identification of anti-inflammatory and neuroprotective compounds. J Alzheimers Dis. 2010; 19(2):451-64. DOI: 10.3233/JAD-2010-1233. View

15.

Millington C, Sonego S, Karunaweera N, Rangel A, Aldrich-Wright J, Campbell I . Chronic neuroinflammation in Alzheimer's disease: new perspectives on animal models and promising candidate drugs. Biomed Res Int. 2014; 2014:309129. PMC: 4083880. DOI: 10.1155/2014/309129. View

16.

Dadhaniya P, Patel C, Muchhara J, Bhadja N, Mathuria N, Vachhani K . Safety assessment of a solid lipid curcumin particle preparation: acute and subchronic toxicity studies. Food Chem Toxicol. 2011; 49(8):1834-42. DOI: 10.1016/j.fct.2011.05.001. View

17.

Tan S, Calani L, Bresciani L, DallAsta M, Faccini A, Augustin M . The degradation of curcuminoids in a human faecal fermentation model. Int J Food Sci Nutr. 2015; 66(7):790-6. DOI: 10.3109/09637486.2015.1095865. View

18.

Wakabayashi M, FISHMAN W . A method for freeing Helix pomatia beta-glucuronidase of sulfatase by simple heat denaturation. Biochim Biophys Acta. 1961; 48:195-7. DOI: 10.1016/0006-3002(61)90535-2. View

19.

Anand P, Kunnumakkara A, Newman R, Aggarwal B . Bioavailability of curcumin: problems and promises. Mol Pharm. 2007; 4(6):807-18. DOI: 10.1021/mp700113r. View

20.

Bhattacharyya S, Mandal D, Saha B, Sen G, Das T, Sa G . Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction. J Biol Chem. 2007; 282(22):15954-64. DOI: 10.1074/jbc.M608189200. View